Tap the Weight-Loss Drug Market With These ETFs

Zacks09-18

The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468531787?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c","is_english":true,"pubTime":"2024-09-18 23:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2468531787","market":"us","top_or_hot":-1,"title":"Tap the Weight-Loss Drug Market With These ETFs","media":"Zacks","content":"<div>\n<p>The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tap-weight-loss-drug-market-150000819.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tap the Weight-Loss Drug Market With These ETFs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTap the Weight-Loss Drug Market With These ETFs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-18 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/tap-weight-loss-drug-market-150000819.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tap-weight-loss-drug-market-150000819.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0823416689.USD","symbol_name":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/tap-weight-loss-drug-market-150000819.html","article_id":"2468531787","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468531787","pubTimestamp":1726671600,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are also vying for a slice of the lucrative business. The latest data from Roche Holdings RHHBY, Novo Nordisk and smaller biotech proved that an oral option could be as effective as injectables.The new drugs in the pipeline are getting approval with potential for improvements such as less frequent administration by pill rather than by injection and fewer side effects .Investors seeking to tap the boom in weight-loss drug treatments could consider Roundhill GLP-1 & Weight Loss ETF OZEM, Amplify Weight Loss Drug & Treatment ETF THNR and GLP-1, Obesity & Cardiometabolic ETF HRTS.Roundhill GLP-1 & Weight Loss ETF Roundhill GLP-1 & Weight Loss ETF is the world’s first GLP-1 ETF and is actively managed. Roundhill believes that weight loss drugs, inclu","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","BK4588":"碎股","BK4550":"红杉资本持仓","LU0079474960.USD":"联博美国增长基金A","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","OZEM":"Roundhill GLP-1 & Weight Loss ETF","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","FDN":"First Trust Dow Jones Internet I","LU0058720904.USD":"联博国际健康护理基金A","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","03165":"华夏欧优股对冲","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4516":"特朗普概念","NVO":"诺和诺德","LLY":"礼来","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0882574139.USD":"富达环球消费行业基金A ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4585":"ETF&股票定投概念","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4533":"AQR资本管理(全球第二大对冲基金)","RHHBY":"罗氏控股","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","BK4007":"制药","HRTS":"Tema Cardiovascular and Metabolics ETF","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD"},"translate_title":"利用这些ETF开拓减肥药市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"THNR":1,"RHHBY":1,"OZEM":1,"HRTS":1,"LLY":0.9,"FDN":0.9,"NVO":0.9,"03165":0.6},"content_text":"The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are also vying for a slice of the lucrative business. The latest data from Roche Holdings RHHBY, Novo Nordisk and smaller biotech proved that an oral option could be as effective as injectables.The new drugs in the pipeline are getting approval with potential for improvements such as less frequent administration by pill rather than by injection and fewer side effects (patients currently report nausea and vomiting and even more serious side effects such as intestinal blockage).Investors seeking to tap the boom in weight-loss drug treatments could consider Roundhill GLP-1 & Weight Loss ETF OZEM, Amplify Weight Loss Drug & Treatment ETF THNR and GLP-1, Obesity & Cardiometabolic ETF HRTS.\nWeight-Loss Pills Take Center Stage\nLast week, Roche’s early Phase 1 clinical trial data showed its pill provided 6.1% weight loss over four weeks. The study's sample size was small, just 12 patients, which is typical of early-stage trials.Meanwhile, Novo Nordisk and another biotech firm, Terns Pharmaceuticals, also released data last week for their oral GLP-1 candidates. Novo Nordisk's oral candidate beat the company's own injectable weight-loss drug, Wegovy. Patients showed 13.1% weight loss after 12 weeks on the pill, compared to 6% after 12 weeks in Wegovy's early trial. Terns’ data showed its early-stage candidate caused 4.9% weight loss over four weeks, which is in line with competitors. However, the company said it would start the second phase of trials next year. According to estimates from analysts at Morningstar and Pitchbook, the market for weight-loss treatment is expected to see 16 new drugs by 2029 that will potentially expand the market size to $200 billion by 2031. Spherical Insights projects the global weight loss supplement market to grow from $28.65 billion in 2023 to $101.83 billion by 2033, at a CAGR of 13.5% (read: ETFs to Profit from the Weight Loss Drug Boom).Obesity has become a major global health crisis impacting every corner of the world, with more than 1 billion individuals living with obesity. Obesity is linked to numerous health risks, including diabetes, heart disease, stroke and cancer.GLP-1 medications mimic the effects of the naturally occurring hormone glucagon-like peptide-1, which is produced in the intestine after eating. These drugs were initially used to treat diabetes but were later found to control blood sugar levels, reduce appetite and promote weight loss.\nOverall, recent studies have shown that GLP-1 drugs have led to a 10-20% reduction in body weight and lowered the risk of heart attack, stroke and cardiovascular death by approximately 20%.\nETFs to Tap\nRoundhill GLP-1 & Weight Loss ETF (OZEM)Roundhill GLP-1 & Weight Loss ETF is the world’s first GLP-1 ETF and is actively managed. Roundhill believes that weight loss drugs, including GLP-1 agonists, represent one of the most revolutionary advancements in the global pharmaceutical industry. OZEM holds 29 stocks in its basket, with a higher concentration on the top two holdings. Roundhill GLP-1 & Weight Loss ETF has accumulated $47.1 million in its asset base since its inception in late May and charges 59 bps in annual fees. It trades in an average daily volume of 34,00 shares (see: all the Healthcare ETFs here).Amplify Weight Loss Drug & Treatment ETF (THNR)Amplify Weight Loss Drug & Treatment ETF provides access to global companies involved in the pharmaceutical manufacturing of GLP-1 agonist or enablers of such businesses. It tracks the VettaFi Weight Loss Drug & Treatment Index and holds 27 stocks in its basket, with a heavy concentration on the top two firms.Amplify Weight Loss Drug & Treatment ETF charges 59 bps in annual fees and has AUM of $4.4 million. It trades in an average daily volume of 3,000 shares. GLP-1, Obesity & Cardiometabolic ETF (HRTS)GLP-1, Obesity & Cardiometabolic ETF seeks to provide long-term growth of capital by investing in GLP-1 and weight loss companies leading the fight against obesity and cardiometabolic diseases. It holds 45 stocks in its basket with a modest concentration on the top firms. GLP-1, Obesity & Cardiometabolic ETF has AUM of $88.6 million and charges 75 bps in annual fees. It trades in a volume of 25,000 shares a day on average.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nRoche Holding AG (RHHBY) : Free Stock Analysis Report\nNovo Nordisk A/S (NVO) : Free Stock Analysis Report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nTema Obesity & Cardiometabolic ETF (HRTS): ETF Research Reports\nAmplify Weight Loss Drug & Treatment ETF (THNR): ETF Research Reports\nRoundhill GLP-1 & Weight Loss ETF (OZEM): ETF Research Reports\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468531787"}